Skip to main content
Xcell Therapeutics Inc. logo

Xcell Therapeutics Inc. — Investor Relations & Filings

Ticker · 373110 ISIN · KR7373110006 KO Manufacturing
Open in API
Filings indexed 86 across all filing types
Latest filing 2026-03-19 Audit Report / Informat…
Country KR South Korea
Listing KO 373110

About Xcell Therapeutics Inc.

https://www.xcell.co.kr/

Xcell Therapeutics Inc. is a company specializing in the research, development, and production of advanced cell culture media. Its primary product line, CellCor™, consists of serum-free, chemically defined media designed to provide an optimal environment for cell culture, particularly for mesenchymal stem cells (MSCs). The technology aims to enhance efficiency and yield for researchers and developers in the fields of cell therapy and regenerative medicine. By offering a serum-free alternative, the company provides a more consistent and defined solution compared to traditional media. Xcell Therapeutics is also expanding its services to become a Contract Development and Manufacturing Organization (CDMO) and is exploring applications for its media in the cultured meat sector.

Recent filings

Filing Released Lang Actions
사업보고서 (2025.12)
Audit Report / Information Classification · 99% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Excel Therapeutics, including the independent auditor's opinion, consolidated financial statements (balance sheet, income statement, cash flow, etc.), and detailed notes. It is not an Annual Report (10-K) as it lacks the broader business overview, management discussion, and other non-financial sections typical of a full 10-K. It is a standalone audit report. FY 2025
2026-03-19 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains information about the meeting date, agenda items (such as approval of financial statements), and proxy solicitation details. While it includes financial statements, these are provided as supporting information for the proxy solicitation rather than as a standalone annual report. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2026-03-11 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Xcell Therapeutics. It contains the agenda for the 11th Annual General Meeting, including the approval of financial statements, election of directors, and remuneration limits. It also includes detailed management information, such as board activity reports, governance details, and financial statements (balance sheets, income statements, etc.) as part of the meeting materials. This document is a standard proxy statement/notice package provided to shareholders to inform them of the upcoming meeting and the items to be voted upon.
2026-03-11 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Excel Therapeutics. It details the date, location, agenda items (such as financial statement approval, director appointments, and articles of incorporation changes), and provides background information on the nominees. This document is a standard proxy solicitation/information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2026-03-11 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing submitted by Excel Therapeutics regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date where many companies hold their AGMs). It explains the reasons for this scheduling conflict and provides notice to shareholders. Since it is a regulatory announcement regarding meeting logistics rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2026-03-11 Korean
합병등종료보고서(자산양수도)
Regulatory Filings Classification · 95% confidence The document is a 'Report of Completion of Merger, etc.' (합병등종료보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details the completion of an asset disposal (sale of shares in Gencurix, Inc.) by Xcell Therapeutics. While the title mentions 'Merger', the content specifically describes a divestment/asset sale transaction. In the context of corporate filings, this is a regulatory disclosure regarding a completed material transaction, which falls under the 'Regulatory Filings' (RNS) category as it is a formal filing of a specific corporate event that does not fit into the other specialized categories like M&A (which usually refers to the merger process itself) or Share Issue.
2026-03-05 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.